TABLE 3.
Odds Ratio of Adherence, Key Findings
| Model 1 (n = 40,632)a | Model 2 (n = 4,157)b | |||
|---|---|---|---|---|
| Odds Ratio | 95% CI | Odds Ratio | 95% CI | |
| Home delivery vs. retail | 1.591c | 1.403-1.804 | 1.946c | 1.461-2.593 |
| Mixed vs. retail | 0.619c | 0.538-0.712 | NA | NA |
| Age | 0.980c | 0.975-0.984 | 0.989 | 0.968-1.011 |
| Female vs. male | 0.981 | 0.925-1.041 | 0.832 | 0.639-1.083 |
| Urbanicity | 1.026 | 0.900-1.169 | 0.623 | 0.305-1.273 |
| Disease burden | 1.013c | 1.006-1.020 | 1.073d | 1.019-1.130 |
| LIS | 1.055 | 0.983-1.131 | 0.863 | 0.554-1.344 |
| OOP costs 30-day adjusted for antidiabetics | 0.996d | 0.994-0.999 | 1.000 | 0.989-1.011 |
| OOP costs 30-day adjusted for antihypertensives | 1.001 | 0.996-1.005 | 1.004 | 0.985-1.024 |
| OOP costs 30-day adjusted for antihyperlipidemics | 0.995c | 0.992-0.997 | 1.006 | 0.993-1.020 |
| Severity of illness for diabetes | 0.713c | 0.683-0.743 | 0.828 | 0.675-1.016 |
| Severity of illness for hypertension | 0.800c | 0.775-0.825 | 0.895 | 0.766-1.046 |
| Prior adherence for antidiabetics | 3.222c | 3.037-3.418 | 3.685c | 2.775-4.895 |
| Prior adherence for antihypertensives | 3.356c | 3.164-3.561 | 3.782c | 2.820-5.073 |
| Prior adherence for antihyperlipidemics | 5.735c | 5.387-6.106 | 4.041c | 2.981-5.479 |
| Average days supply per claim for antidiabetics | 1.004d | 1.001-1.006 | NA | NA |
| Average days supply per claim for antihypertensives | 1.011c | 1.009-1.013 | NA | NA |
| Average days supply per claim for antihyperlipidemics | 1.001 | 0.999-1.003 | NA | NA |
a Model 1 presents the results of the analysis including differential days supply across all patients.
b Model 2 presents the results of the comparison of 90-day retail with 90-day home delivery for patients filling their prescriptions exclusively through 1 channel (either home delivery or retail).
c Significant at P < 0.001.
d Significant at P < 0.01.
CI = confidence interval; LIS = low-income subsidy; NA = not applicable; OOP = out of pocket.